Redefining treatment for knee osteoarthritis Sussex Life

For many of the 8.5 million people in the UK living with knee osteoarthritis (OA),³ life is hampered by constant pain, limited mobility, and difficulty with simple, everyday tasks. But there’s hope with Arthrosamid® – a permanent injectable hydrogel⁴ that delivers long-lasting, proven pain relief without surgery^1-2 -  redefining treatment for knee OA, with experts calling it a ‘game-changer.’

People delay seeking help for knee pain, assuming it’s an unavoidable part of ageing. But Arthrosamid® offers patients a new pathway. Supported by more than two decades of research,⁵ Arthrosamid® is suitable, safe and effective ^1,2,6-10 for most patients with knee OA, administered via a simple, one-step procedure under local anaesthetic and gives a significant, long-lasting reduction in knee OA pain – even four years post-treatment.¹

What the experts say

Mr Sebastian Dawson-Bowling, Consultant and Specialist Hip and Knee Surgeon at the Nuffield Health Brighton Hospital, one of many clinics in the area offering the Arthrosamid® treatment, says: “I’ve treated patients with Arthrosamid® and have seen them experience significant reductions in pain, as well as improvements in their mobility, and overall quality of life.

“In contrast to other treatments, Arthrosamid® appears to be offering patients longer-lasting respite from the pain and immobility of knee osteoarthritis and, in many cases, avoiding or delaying the need for surgery. I believe it’s setting a real benchmark in the area of orthopaedics, offering hope and optimism to many of those living with this condition.”

^References:

^{1. Bliddal, H., et al. (2024) A Prospective Study of Polyacrylamide Hydrogel Injection for Knee Osteoarthritis: Results From 4 Years After Treatment. Presented at EORS 2024.}

^{2. Bliddal, H., et al. (2024) 3-year follow-up from a randomized controlled trial of intra-articular polyacrylamide hydrogel injection in subjects with knee osteoarthritis. Poster LB-31, OARSI 2024 World Congress on Osteoarthritis. 3. nice.org.uk/guidance/cg177/documents/osteoarthritis-update-final-scope2}

^{4. Christensen, L., et al. (2016). Histological Appearance of the Synovial Membrane after Treatment of Knee Osteoarthritis with Polyacrylamide Gel Injections: A Case Report. Journal of Arthritis. Vol 5: 217.}

^{5. Data on file}

^{6. Bliddal, H., et al. (2021) Polyacrylamide Hydrogel Injection for Knee Osteoarthritis: A 6 Months Prospective Study. J Orthop Res Ther. Vol 6 (2). 1188. ISSN 2575-8241}

^{7. Bliddal, H., Beier, J., Hartkopp, A. et al. Effectiveness and safety of polyacrylamide hydrogel injection for knee osteoarthritis: results from a 12-month follow up of an open-label study. J Orthop Surg Res 19, 274 (2024).}

^{8. Bliddal, H., et al. (2022). A Prospective Study of Polyacrylamide Hydrogel Injection for Knee Osteoarthritis: Results From 2 Years After Treatment. Poster presented at OARSI 2022. Osteoarthritis and Cartilage. Vol 30(1): S371-S372. DOI:10.1016/j.joca.2022.02.499.}

^{9. Bliddal, H., et al. (2023) A Prospective Study of Polyacrylamide Hydrogel Injection for Knee Osteoarthritis: Results From 3 Years After Treatment. Osteoarthritis and Cartilage. Vol 31(5): 682-683.}

^{10. Bliddal, H., et al. (2022). One-year performance of polyacrylamide hydrogel vs. hyaluronic acid: A randomised controlled study. Osteoarthritis and Cartilage, Vol 30, S1, S371.}

^{OUS/ARTHRO/SEP2024/181}